Equity Overview
Price & Market Data
Price: $1.66
Daily Change: $0.00 / 0.00%
Daily Range: $1.38 - $1.69
Market Cap: $1,063,304,064
Daily Volume: 33,581,583
Performance Metrics
1 Week: 7.79%
1 Month: 12.93%
3 Months: 25.76%
6 Months: 17.73%
1 Year: 4.40%
YTD: 25.76%
Company Details
Employees: 258
Sector: Health technology
Industry: Biotechnology
Country: United States
Details
Geron Corporation, a commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology. The company's product pipeline includes RYTELO, a telomerase inhibitor for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia; IMerge which is in Phase 3 clinical trial for the treatment of lower-risk myelodysplastic syndromes; IMpactMF that is in Phase 3 for the treatment of relapsed/refractory myelofibrosis; Impress which is in Phase 2 clinical trial to treat higher risk myelodysplastic syndromes and acute myeloid leukemia (AML); IMproveMF which is in Phase 1 clinical trial for the treatment of frontline myelofibrosis; and IMAGINE which is in phase 1/2 clinical trial for the treatment of relapsed/refractory AML. Geron Corporation was incorporated in 1990 and is headquartered in Foster City, California.